A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)

被引：10

作者：

McDermott, D. F. ^{[1
]}

Infante, J. R. ^{[2
]}

Chowdhury, S. ^{[3
]}

Voss, M. H. ^{[4
]}

Motzer, R. J. ^{[4
]}

Perini, R. F. ^{[5
]}

Morosky, A. ^{[5
]}

Zheng, F. F. ^{[6
]}

White, B. C. ^{[6
]}

Wang, Q. ^{[6
]}

Jewell, R. C. ^{[7
]}

Rini, B. I. ^{[8
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Oncol, Boston, MA 02215 USA

[2] Tennesee Oncol, Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[3] Sarah Cannon Res Inst, Oncol, London, England

[4] Mem Sloan Kettering Canc Ctr, Oncol, New York, NY 10021 USA

[5] Merck & Co Inc, Oncol, N Wales, PA USA

[6] GlaxoSmithKline, Oncol, Collegeville, PA USA

[7] GlaxoSmithKline, Oncol, Res Triangle Pk, NC USA

[8] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

来源：

关键词：

D O I：

10.1016/S0959-8049(16)31440-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2622

引用

页码：S519 / S520

页数：2